A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

May 9, 2022

Primary Completion Date

March 22, 2023

Study Completion Date

December 21, 2023

Conditions
HypertriglyceridemiaAtherosclerotic Cardiovascular DiseaseSevere Hypertriglyceridemia
Interventions
DRUG

Olezarsen

Olezarsen will be administered by SC injection.

DRUG

Placebo

Olezarsen-matching placebo will be administered once every 4 weeks by SC injection for up to 49 weeks.

Trial Locations (24)

19446

Green and Seidner Family Practice Associates, Lansdale

20110

Manassas Clinical Research Center, Manassas

23504

York Clinical Research LLC, Norfolk

29566

Main Street Physicians Care Waterway, Little River

31904

IACT Health, Columbus

32792

Research Physicians Network Alliance, Winter Park

33184

De La Cruz Research Center, Miami

33434

Excel Medical Clinical Trials, LLC, Boca Raton

34652

Suncoast Clinical Research, Inc., New Port Richey

37388

Tennessee Center for Clinical Trials, Tullahoma

40213

Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville

48504

Aa Mrc, Llc, Flint

51501

West Broadway Clinic, Council Bluffs

57702

Health Concepts, Rapid City

60031

Clinical Investigation Specialist, Gurnee

60201

Evanston Premier Healthcare Research, Evanston

75149

Southern Endocrinology Associates, Mesquite

89121

Clinical Research of South Nevada, Las Vegas

89148

Palm Research Center, Inc., Las Vegas

91763

Catalina Research Institute, LLC, Montclair

95648

Clinical Trials Research, Lincoln

N7t 4X3

Bluewater Clinical Research Group Inc, Sarnia

G7H 7K9

Ecogene-21, Chicoutimi

G1V 4W2

Clinique des Maladies Lipidiques de Quebec Inc., Québec

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY